Note: Testing for HIV-1 and HIV-2 must be perfo rmed at sites, only where mandated by local requirements. Pregnancy Test XFor WOCBP only; serum/urine pregnancy test m ust be performed (urine pregnancy test: minimum sensitivity 25 IU/L or e quivalent units of hCG) at screening and within 24 hours prior to dosing. Th e serum pregnancy test may be completed on the first day of treatment provided t hat the results are available before the start of study treatment. If performed w ithin 24 hours of dosing on Cycle 1 Day 1, then Cycle 1 Day 1 pregnancy tes t is not required. Follicle-stimulating HormoneXWomen only, if needed to document postmenopa usal status (refer to Appendix 4 ). Tetanus booster XTo be performed on all participants in preliminar y safety cohort, Parts A, B1, B2, C1, C2, D and E, using an approved tetanus v accine. The tetanus booster must be administered betwee n Day -7 and Day -3, prior to dosing. A tetanus booster does not have to be adm inistered if the participant received a tetanus booster within 6 weeks of start ing study drug. AE Reporting and Concomitant Medication Assessments Clinical Complaints XComplaints related to the disease under study coll ected during the 2 weeks prior to dosing. Revised Protocol No.: 04 Date: 31-May-2019 21 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 2-1: Screening Procedural Outline (CA021002) ProcedureScreening Visit (Day -28 to -1)Day -7 to -3 VisitDay -3 to -1 VisitNotes Concomitant Medications XAll concomitant medications taken within 4 week s prior to study treatment administration must be recorded on the CRF. Monitor for SAEs XAll SAEs must be collected from the date of parti cipant’s written consent until 100 days after last dose of study drug.